Abstract
In extensive studies of patients with Bartter’s and Gitelman’s syndromes, we have shown biochemical abnormalities in angiotensin II (Ang II) short- and long-term cell signalling, which depict a mirror image of those found in hypertension. The information obtained from the study of this human model of altered vascular tone regulation shows that it can be used to gather more general data and/or confirm mechanistic details of the cellular and biochemical events involved in the pathophysiology of vascular tone control, and to shed light on the multiplicity of the Ang II signalling-related mechanisms responsible for the pathophysiology of hypertension and its long-term complications, such as cardiovascular remodelling and atherogenesis.
Similar content being viewed by others
References
Touyz RM. Molecular and cellular mechanisms regulating vascular function and structure: implications in the pathogenesis of hypertension. Can J Cardiol 2000; 16: 1137–46
Johns DG, Dorrance AM, Leite R, et al. Novel signaling pathways contributing to vascular changes in hypertension. J Biomed Sci 2000; 7: 431–43
Wilcox CS. Reactive oxygen species: roles in blood pressure and kidney function. Curr Hypertens Rep 2002; 4: 160–6
Touyz RM. Role of angiotensin II in regulating vascular structural and functional changes in hypertension. Curr Hypertens Rep 2003; 5: 155–64
Dzau VJ. Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension 2001; 37: 1047–52
Griendling KK, Soresen D, Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res 2000; 86: 494–501
Nath KA, Grande J, Croatt A, et al. Redox regulation of renal DNA synthesis, transforming growth factor-beta-1 and collagen gene expression. Kidney Int 1998; 53: 367–81
Abe J, Berk BC. Reactive oxygen species as mediators of signal transduction in cardiovascular disease. Trends Cardio Med 1998; 8: 59–64
Maines MD. The heme oxygenase system: a regulator of second messenger gases. Annu Rev Pharmacol Toxicol 1997; 37: 517–54
Immenschuh S, Ramadori G. Gene regulation of heme oxygenase-1 as a therapeutic target. Biochem Pharmacol 2000; 60: 1121–8
Calò L, Davis PA, Semplicini A. Regulation of vascular tone in Bartter’s and Gitelman’s syndromes. Crit Rev Clin Lab Sci 2000; 37: 503–23
Naesens M, Steels P, Verberckmoes R, et al. Bartter’s and Gitelman’s syndromes: from gene to clinic. Nephron Physiol 2004; 96: 65–78
Calò L, Davis PA, Semplicini A. Bartter’s/Gitelman’s syndrome: a model for the relationships between hypertension, angiotensin II, oxidative stress and remodeling. Clin Nephrol 2003; 59: 393–4
Calò LA, Pagnin E, Davis PA, et al. Oxidative stress related factors in Bartter’s and Gitelman’s syndromes: relevance for angiotensin II signalling. Nephrol Dial Transplant 2003; 18: 1518–25
Pagnin E, Davis PA, Sartori M, et al. Rho kinase and PAI-1 in Bartter’s/Gitelman’s syndromes: relationship to angiotensin II signaling. J Hypertens 2004; 22: 1963–9
Calò LA, Pagnin E, Davis PA, et al. Increased expression of regulator of G protein signaling-2 (RGS-2) in Bartter’s/Gitelman’s syndrome: a role in the control of vascular tone and implication for hypertension. J Clin Endocrinol Metab 2004; 89: 4153–7
Calò L, Ceolotto G, Milani M, et al. Abnormalities of Gq-mediated cell signaling in Bartter and Gitelman syndromes. Kidney Int 2001; 60: 882–9
Calò L, Davis PA, Semplicini A. Reduced content of alpha subunit of Gq protein in monocytes of Bartter and Gitelman syndromes: relationship with vascular hyporeactivity. Kidney Int 2002; 61: 353–4
Calò L, D’Angelo A, Cantaro S, et al. Intracellular calcium signalling and vascular reactivity in Bartter’s syndrome. Nephron 1996; 72: 570–3
Di Virgilio F, Calò L, Cantaro S, et al. Resting and stimulated cytosolic free calcium levels in neutrophils from patients with Bartter’s syndrome. Clin Sci 1987; 72: 483–8
Calò L, Davis PA, Milani M, et al. Increased endothelial nitric oxide synthase mRNA level in Bartter’s and Gitelman’s syndrome: relationship to vascular reactivity. Clin Nephrol 1999; 51: 12–7
Calò L, D’Angelo A, Cantaro S, et al. Increased urinary NO2-/NO3- and cyclic GMP levels in patients with Bartter’s syndrome: relationship to vascular reactivity. Am J Kidney Dis 1996; 27: 874–9
Calò L, Cantaro S, Calabro A, et al. Endothelium-derived vasoactive substances in Bartter’s syndrome. Angiology 1995; 46: 905–13
Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993; 329: 2002–12
Calò L, Sartore G, Bassi A, et al. Reduced susceptibility of low-density lipoprotein to oxidation in patients with overproduction of nitric oxide (Bartter’s and Gitelman’s syndrome). J Hypertens 1998; 16: 1001–8
Berridge MJ. Inositol trisphosphate and calcium signalling. Nature 1993; 361: 315–25
Davis MJ, Hill MH. Signaling mechanisms underlying the vascular myogenic response. Physiol Rev 1999; 70: 387–423
Ciedel CL. Regulation of vascular smooth muscle contraction. Fed Proc 1984; 43: 2390–8
Benjamin N, Vallance P. Local control of human peripheral vascular tone: implications for drug therapy. Clin Sci 1991; 80: 183–90
Somlyo AP, Somlyo AV. Flash photolysis studies of excitation-contraction coupling, regulation, and contraction in smooth muscle. Annu Rev Physiol 1990; 52: 857–74
Van Breeman C, Saida K. Cellular mechanisms regulating [Ca2+]i smooth muscle. Annu Rev Physiol 1989; 51: 315–29
Ives HE. Ion transport defects and hypertension: where is the link? Hypertension 1989; 14: 590–7
Griendling KK, Ushio-Fukai M, Lassegue B, et al. Angiotensin II signaling in vascular smooth muscle: new concepts. Hypertension 1997; 29: 366–73
Singer WD, Brown HA, Sternweis PC. Regulation of eukaryotic phosphatidylinositol-specific phospholipase C and D. Annu Rev Biochem 1997; 66: 475–509
Somlyo AV, Bond M, Somlyo AP, et al. Inositol trisphosphate-induced calcium release and contraction in vascular smooth muscle. Proc Natl Acad Sci U S A 1985; 82: 5231–5
Galizzi JP, Qar J, Fosset M, et al. Regulation of calcium currents in aortic smooth muscle cells by protein kinase C activators (diacylglycerol and phorbol esters) and by peptides (vasopressin and bombesin) that stimulate phosphoinositide breakdown. J Biol Chem 1987; 262: 6947–50
Cole WC, Clement-Chomienne O, Aiello EA. Regulation of 4 aminopyridine-sensitive, delayed rectified K+ channels in vascular smooth muscle by phosphorylation. Biochem Cell Biol 1996; 74: 439–47
Boulanger MC, Vanhoutte PM. G protein and endothelium-dependent relaxations. J Vasc Res 1997; 34: 175–85
Palmer RM, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 1988; 333: 664–6
Marsden PA, Heng HHQ, Scherer SW, et al. Structure and chromosomal localization of the human constitutive endothelial nitric oxide synthase gene. J Biol Chem 1993; 268: 17478–88
Clementi E. Role of nitric oxide and its intracellular signalling pathways in the control of Ca2+ homeostasis. Biochem Pharmacol 1998; 55: 713–8
Davis PA, Calò L. Is atherosclerosis a no NO state? Circulation 1999; 20: 2709–12
Calò L, Felice M, Cantaro S, et al. Inhibition of furosemide-sensitive cation transport and activation of sodium-lithium exchange by endogenous circulating factor(s) in Bartter’s and Gitelman’s syndromes. J Hypertens 1997; 15: 1407–13
Akar F, Skinner E, Klein JD, et al. Vasoconstrictors and nitrovasodilators reciprocally regulate the Na+-K+-Cl- cotransporter in rat aorta. Am J Physiol 1999; 276: C1383–90
Sprang SR. G protein mechanisms: insights from structural analysis. Annu Rev Biochem 1997; 66: 639–78
Ali N, Agrawal DK. Guanine nucleotide binding regulatory proteins: their characteristics and identification. J Pharmacol Toxicol Method 1994; 32: 187–96
Mironneau J, Macrez N. Specificity of Gq and G11 protein signaling in vascular myocites. Trends Cardio Med 1998; 8: 157–62
Force T, Bonventre JV. Growth factors and mitogen-activated protein kinases. Hypertension 1998; 31: 152–61
Hepler RJ. Emerging roles for RGS proteins in cell signalling. Trends Pharmacol Sci 1999; 20: 376–82
Zhong H, Neubig RR. Regulator of G protein signalling proteins: novel multifunctional drug targets. J Pharmacol Exp Ther 2001; 297: 837–45
Ross EM, Wilkie TM. GTPase-activating proteins for heterotrimeric G proteins: regulators of G protein signaling (RGS) and RGS-like proteins. Annu Rev Biochem 2000; 69: 795–827
Heximer SP, Knutsen RH, Sun X, et al. Hypertension and prolonged vasoconstrictor signalling in RGS2-deficient mice. J Clin Invest 2003; 111: 445–52
Yoshida H, Kakuchi J, Yoshikawa N, et al. Angiotensin II type 1 receptor gene abnormality in a patient with Bartter’s syndrome. Kidney Int 1994; 46: 1505–9
Kojda G, Harrison D. Interactions between NO and reactive oxygen species: pathophysiological importance in atherosclerosis, hypertension, diabetes and heart failure. Cardiovasc Res 1999; 43: 562–71
Fukata Y, Amano M, Kaibuki K. Rho-Rho-kinase pathway in smooth muscle contraction and cytoskeletal reorganization of non-muscle cells. Trends Pharmacol Sci 2001; 22: 32–9
Sward K, Mita M, Wilson DP, et al. The role of RhoA and Rho-associated kinase in vascular smooth muscle contraction. Curr Hypertens Rep 2003; 5: 66–72
Leung T, Manser E, Tan L, et al. A novel serine/threonine kinase binding the Ras-related RhoA GTPase which translocates the kinase to peripheral membranes. J Biol Chem 1995; 270: 29051–4
Matsui T, Amano M, Yamamoto T, et al. Rho-associated kinase, a novel serine/threonine kinase, as a putative target for small GTP binding protein Rho. EMBO J 1996; 15: 2208–16
Masumoto A, Hirooka Y, Shimokawa H, et al. Possible involvement of Rho-kinase in the pathogenesis of hypertension in humans. Hypertension 2001; 38: 1307–10
Takeda K, Ichiki T, Tokunou T, et al. Critical role of Rho-kinase and MEK-ERK pathways for angiotensin II-induced plasminogen activator inhibitor type-1 gene expression. Arterioscler Thromb Vasc Biol 2001; 21: 868–73
Jin L, Ying Z, Webb RC. Activation of Rho/Rho kinase signaling pathway by reactive oxygen species in rat aorta. Am J Physiol Heart Circ Physiol 2004; 287: H1495–500
Ying Z, Jin L, Dorrance AM, et al. Increased expression of mRNA for regulator of G protein signaling domain-containing Rho guanine nucleotide exchange factors in aorta from stroke-prone spontaneously hypertensive rats. Am J Hypertens 2004; 17: 981–5
Gong MC, Gorenne I, Read P, et al. Regulation by GDI of RhoA/Rho-kinase-induced Ca2+ sensitization of smooth muscle myosin II. Am J Physiol Cell Physiol 2001; 28: C257–69
Kobayashi N, Nakano S, Mita S, et al. Involvement of Rho-kinase pathway for Ang II-induced plasminogen activator inhibitor gene expression and cardiovascular remodelling in hypertensive rats. J Pharmacol Exp Ther 2002; 301: 459–66
Jarad G, Simske JS, Sedor JR, et al. Nucleic acid-based techniques for post-transcriptional regulation of molecular targets. Curr Opin Nephrol Hypertens 2003; 12(4): 415–21
Erne P, Bolli P, Burgisser E, et al. Correlation of platelet calcium with blood pressure: effect of antihypertensive therapy. N Engl J Med 1984; 310: 1084–8
Sharma RV, Bhalla RC. Calcium and abnormal reactivity of vascular smooth muscle in hypertension. Cell Calcium 1988; 9: 267–74
Suzuki H, Ikenaga H, Hishikawa K, et al. Increases in NO2-/NO3- excretion in the urine as an indicator of the release of endothelium-derived relaxing factor during elevation of blood pressure. Clin Sci 1992; 82: 631–4
Panza JA, Quyyumi AA, Brush Jr JE, et al. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med 1990; 323: 22–7
Lin KF, Chao L, Chao J. Prolonged reduction of high blood pressure with human nitric oxide synthase gene delivery. Hypertension 1997; 30(3 Pt 1): 307–13
Keys JR, Greene EA, Koch WJ, et al. Gq-coupled receptor agonists mediate cardiac hypertrophy via the vasculature. Hypertension 2002; 40: 660–6
Tang M, Wang G, Lu P, et al. Regulator of G-protein signaling-2 mediates vascular smooth muscle relaxation and blood pressure. Nat Med 2003; 9: 1506–12
Fukui T, Ishizaka N, Rajagopalan S, et al. p22phox mRNA expression and NADPH oxidase activity are increased in aortas from hypertensive rats. Circ Res 1997; 80: 45–51
Fortuño A, Olivan S, Beloqui O, et al. Association of increased phagocytic NADPH oxidasedependent superoxide production with diminished nitric oxide generation in essential hypertension. J Hypertens 2004; 22: 2169–75
Porreca E, Di Febbo C, Mincione G, et al. Increased transforming growth factor-production and gene expression by peripheral blood monocytes of hypertensive patients. Hypertension 1997; 30: 134–9
Suthanthiran M, Li B, Song JO, et al. Transforming growth factor-1 hyperexpression in African-American hypertensives: a novel mediator of hypertension and/or target organ damage. Proc Natl Acad Sci U S A 2000; 97: 3479–84
Laviades C, Varo N, Diez J. Transforming growth factor- in hypertensives with cardiorenal damage. Hypertension 2000; 36: 517–22
Ndisang JF, Zhao W, Wang R. Selective regulation of blood pressure by heme oxygenase-1 in hypertension. Hypertension 2002; 40: 315–21
Durante W. Heme oxygenase-1 in growth control and its clinical application to vascular disease. J Cell Physiol 2003; 195: 373–82
Uehata M, Ishizaki T, Satoh H, et al. Calcium sensitization of smooth muscle mediated by a Kho-associated protein kinase in hypertension. Nature 1997; 389: 990–4
Wolfrum S, Dendorfer A, Rikitake Y, et al. Inhibition of Rho-kinase leads to rapid activation of phosphatidylinositol 3 kinase/protein kinase Akt and cardiovascular protection. Arterioscler Thromb Vasc Biol 2004; 24: 1842–7
Kaikita K, Fogo AB, Ma L, et al. Plasminogen activator inhibitor-1 deficiency prevents hypertension and vascular fibrosis in response to long-term nitric oxide synthase inhibition. Circulation 2001; 104: 839–44
Acknowledgements
Studies included in this review have been supported in part by a grant from the Italian Society of Hypertension (SIIA) and by a grant from Regione Veneto to L.A. Calò and in part by a grant from MURST to A. Semplicini.
The authors have no conflicts of interest directly related to the contents of this review.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Calò, L.A., Pessina, A.C. & Semplicini, A. Angiotensin II Signalling in Bartter’s and Gitelman’s Syndromes. High Blood Press Cardiovasc Prev 12, 17–26 (2005). https://doi.org/10.2165/00151642-200512010-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151642-200512010-00004